Cargando…

The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)

In this report we show that mithramycin considerably increases the direct cytotoxic effect of tumour necrosis factor (TNF) on tumour cells in vitro. Sensitisation to TNF-induced apoptosis was prevented by the broad caspase inhibitor zVAD-fmk, whereas overexpression of Bcl-2 had no effect. Mithramyci...

Descripción completa

Detalles Bibliográficos
Autores principales: Duverger, V, Murphy, A-M, Sheehan, D, England, K, Cotter, T G, Hayes, I, Murphy, F J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409467/
https://www.ncbi.nlm.nih.gov/pubmed/15138489
http://dx.doi.org/10.1038/sj.bjc.6601824
_version_ 1782155771211939840
author Duverger, V
Murphy, A-M
Sheehan, D
England, K
Cotter, T G
Hayes, I
Murphy, F J
author_facet Duverger, V
Murphy, A-M
Sheehan, D
England, K
Cotter, T G
Hayes, I
Murphy, F J
author_sort Duverger, V
collection PubMed
description In this report we show that mithramycin considerably increases the direct cytotoxic effect of tumour necrosis factor (TNF) on tumour cells in vitro. Sensitisation to TNF-induced apoptosis was prevented by the broad caspase inhibitor zVAD-fmk, whereas overexpression of Bcl-2 had no effect. Mithramycin also potentiated cell death induced by Fas agonistic antibodies. In contrast, mithramycin reduced the percentage of cells undergoing apoptosis due to factor withdrawal. TNF-induced activation of NF-kappaB (NF-κB)-dependent gene expression was not modulated by mithramycin treatment. Concomitantly with the increased sensitivity, the protein level of the short-spliced cFLIP variant was downregulated. These results indicate that mithramycin enhances TNF-induced cell death in an NF-κB-independent manner, and suggest that the Fas-associated death domain protein plays a crucial role in the TNF-sensitising effect of mithramycin.
format Text
id pubmed-2409467
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24094672009-09-10 The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) Duverger, V Murphy, A-M Sheehan, D England, K Cotter, T G Hayes, I Murphy, F J Br J Cancer Experimental Therapeutics In this report we show that mithramycin considerably increases the direct cytotoxic effect of tumour necrosis factor (TNF) on tumour cells in vitro. Sensitisation to TNF-induced apoptosis was prevented by the broad caspase inhibitor zVAD-fmk, whereas overexpression of Bcl-2 had no effect. Mithramycin also potentiated cell death induced by Fas agonistic antibodies. In contrast, mithramycin reduced the percentage of cells undergoing apoptosis due to factor withdrawal. TNF-induced activation of NF-kappaB (NF-κB)-dependent gene expression was not modulated by mithramycin treatment. Concomitantly with the increased sensitivity, the protein level of the short-spliced cFLIP variant was downregulated. These results indicate that mithramycin enhances TNF-induced cell death in an NF-κB-independent manner, and suggest that the Fas-associated death domain protein plays a crucial role in the TNF-sensitising effect of mithramycin. Nature Publishing Group 2004-05-17 2004-04-20 /pmc/articles/PMC2409467/ /pubmed/15138489 http://dx.doi.org/10.1038/sj.bjc.6601824 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Experimental Therapeutics
Duverger, V
Murphy, A-M
Sheehan, D
England, K
Cotter, T G
Hayes, I
Murphy, F J
The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)
title The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)
title_full The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)
title_fullStr The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)
title_full_unstemmed The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)
title_short The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)
title_sort anticancer drug mithramycin a sensitises tumour cells to apoptosis induced by tumour necrosis factor (tnf)
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409467/
https://www.ncbi.nlm.nih.gov/pubmed/15138489
http://dx.doi.org/10.1038/sj.bjc.6601824
work_keys_str_mv AT duvergerv theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT murphyam theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT sheehand theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT englandk theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT cottertg theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT hayesi theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT murphyfj theanticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT duvergerv anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT murphyam anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT sheehand anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT englandk anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT cottertg anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT hayesi anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf
AT murphyfj anticancerdrugmithramycinasensitisestumourcellstoapoptosisinducedbytumournecrosisfactortnf